$NTRA

Fesko John sold $292K of NTRA

Fesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 1,438 shares of Natera, Inc. (NTRA) at $202.84 ($0.29M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fesko John
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed event is an officer open-market sale under a pre-arranged 10b5-1 plan, which typically reduces the signal value versus discretionary selling.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a durable repricing without additional company catalysts.

03

What to watch

The article provides only the sale details; it does not include any concurrent buy transactions, changes in guidance, or new company events that would justify a fundamental repricing.

Relevance 3/10Novelty 3/10Timing: Filed 2026-05-28, disclosing a sale executed 2026-05-26.

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera Form 4 shows officer Fesko John sold 1,438 shares at $202.8398 on 2026-05-26 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly under a pre-arranged Rule 10b5-1 plan, with no accompanying company news or guidance change.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales can be interpreted as diversification or liquidity needs rather than negative fundamentals, especially when tied to a 10b5-1 plan.

Key entities

  • Natera, Inc.

    Company whose Form 4 insider sale is disclosed.

  • Fesko John

    Natera officer (President, Chief Business Officer) who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.